118 related articles for article (PubMed ID: 2062521)
1. Penetration of erythromycin into periapical lesions after repeated doses of erythromycin acistrate and erythromycin stearate: a pilot study.
Tuominen RK; Lehtinen R; Peltola J; Wikberg R; Gordin A; Kokkonen P; Pohto P
Oral Surg Oral Med Oral Pathol; 1991 Jun; 71(6):684-8. PubMed ID: 2062521
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of erythromycin, 2'-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate.
Gordin A; Männistö PT; Antikainen R; Savolainen S; Ylikoski J; Kokkonen P; Rauramaa V
Antimicrob Agents Chemother; 1988 Jul; 32(7):1019-24. PubMed ID: 3190191
[TBL] [Abstract][Full Text] [Related]
3. Erythromycin and 2'-acetyl erythromycin concentrations in plasma and pelvic tissues after repeated doses of erythromycin acistrate.
Lehtonen L; Wikberg R; Karhunen M; Kokkonen P; Tuominen R
Arzneimittelforschung; 1993 Jan; 43(1):53-6. PubMed ID: 8447849
[TBL] [Abstract][Full Text] [Related]
4. Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis.
Savolainen S; Männistö PT; Gordin A; Antikainen R; Haataja H; Tuominen RK; Ylikoski J
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():73-84. PubMed ID: 3391878
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of erythromycin acistrate (2'-acetyl erythromycin stearate) and erythromycin stearate in experimental infections in mice.
Männistö PT; Hanhijärvi H; Havas A; Vuorela A; Komulainen H; Rauramaa V
J Pharmacol Exp Ther; 1989 Sep; 250(3):1028-33. PubMed ID: 2778707
[TBL] [Abstract][Full Text] [Related]
6. Time course of the antibacterial activity of erythromycin stearate and erythromycin acistrate against two Staphylococcus aureus strains in vitro.
Korkeala H; Männistö PT
J Antimicrob Chemother; 1988 Aug; 22(2):127-33. PubMed ID: 3182415
[TBL] [Abstract][Full Text] [Related]
7. Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers.
Männistö PT; Taskinen J; Ottoila P; Solkinen A; Vuorela A; Nykänen S
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():33-43. PubMed ID: 3391874
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic concentration in suction skin blister fluid and saliva after repeated dosage of erythromycin acistrate and erythromycin base.
Tuominen RK; Männistö PT; Solkinen A; Vuorela A; Pohto P; Haataja H
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():57-65. PubMed ID: 3391876
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate.
Marvola M; Nykänen S; Nokelainen M
Pharm Res; 1991 Aug; 8(8):1056-8. PubMed ID: 1656422
[TBL] [Abstract][Full Text] [Related]
10. Erythromycin acistrate and erythromycin stearate in the treatment of non-gonococcal urethritis.
Rostila T; Visa K; Gordin A; Antikainen R
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():113-9. PubMed ID: 3391873
[TBL] [Abstract][Full Text] [Related]
11. Effect of food on absorption and hydrolysis of erythromycin acistrate.
Järvinen A; Nykänen S; Mattila J; Haataja H
Arzneimittelforschung; 1992 Jan; 42(1):73-6. PubMed ID: 1586385
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema.
Salo OP; Gordin A; Brandt H; Antikainen R
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():101-6. PubMed ID: 3391871
[TBL] [Abstract][Full Text] [Related]
13. The influence of food on the bioavailability of new formulations of erythromycin stearate and base.
Rutland J; Berend N; Marlin GE
Br J Clin Pharmacol; 1979 Oct; 8(4):343-7. PubMed ID: 508509
[TBL] [Abstract][Full Text] [Related]
14. Comparative liver toxicity of various erythromycin derivatives in animals.
Viluksela M; Hanhijärvi H; Husband RF; Kosma VM; Collan Y; Männistö PT
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():9-27. PubMed ID: 3391880
[TBL] [Abstract][Full Text] [Related]
15. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia.
Wiesner B; Wilen-Rosenqvist G; Lehtonen L
Arzneimittelforschung; 1993 Sep; 43(9):1014-7. PubMed ID: 8240450
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerance of erythromycin acistrate in the treatment of acute exacerbations of chronic bronchitis in the elderly.
Forsén KO; Wikberg R; Lehtonen L
Chemotherapy; 1993; 39(6):443-52. PubMed ID: 8222874
[TBL] [Abstract][Full Text] [Related]
17. Erythromycin stearate, 1.5 g, for the oral prophylaxis of streptococcal bacteraemia in patients undergoing dental extraction: efficacy and tolerance.
Shanson DC; Akash S; Harris M; Tadayon M
J Antimicrob Chemother; 1985 Jan; 15(1):83-90. PubMed ID: 3882657
[TBL] [Abstract][Full Text] [Related]
18. Comparison of erythromycin acistrate and enterocoated erythromycin base in acute respiratory infections.
Gordin A; Kalima S; Hulmi S; Mäkelä P; Antikainen R
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():85-92. PubMed ID: 3391879
[TBL] [Abstract][Full Text] [Related]
19. Human pharmacokinetics of erythromycin propionate-N-acetylcysteinate: comparative evaluation with erythromycin stearate and N-acetylcysteine.
De Bernardi M; Feletti F; Gazzani G; Fregnan GB
Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):444-7. PubMed ID: 3198299
[TBL] [Abstract][Full Text] [Related]
20. Histopathological profile of surgically removed persistent periapical radiolucent lesions of endodontic origin.
Love RM; Firth N
Int Endod J; 2009 Mar; 42(3):198-202. PubMed ID: 19228208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
